CNS Pharmaceuticals Inc. Announces 1-for-12 Reverse Stock Split

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in treatments for brain and central nervous system cancers, has announced a 1-for-12 reverse stock split set to take effect on July 22, 2025. This strategic move will see every twelve shares of CNSP's common stock converted into one share, with corresponding adjustments made to warrants and equity awards to maintain proportionality. The company's stock will continue to trade under the ticker symbol CNSP but will be assigned a new CUSIP number: 18978H508. In line with this adjustment, CNS Pharmaceuticals will not issue fractional shares; instead, shareholders entitled to fractional shares will receive a cash payment. The reverse stock split will also reduce the company's authorized share count to 25 million, while the par value per share remains unchanged at $0.001. This decision is part of CNS Pharmaceuticals' broader strategy to streamline its capital structure and ensure a uniform effect across all shareholders. For further details, the full press release can be accessed here.